Evidence Tables

Evidence Table 1. Studies of self-administered drugs for the treatment of acute migraine

Evidence Table 2. Efficacy of NSAIDs and other non-opiate analgesics

Evidence Table 3. Efficacy of ergot alkaloids

Evidence Table 4. Efficacy of DHE nasal spray

Evidence Table 5. Efficacy of subcutaneous sumatriptan -- HA relief at 1 hr

Evidence Table 6. Efficacy of subcutaneous sumatriptan -- HA relief at 2 hrs

Evidence Table 7. Efficacy of subcutaneous sumatriptan -- complete relief at 1 hr

Evidence Table 8. Efficacy of subcutaneous sumatriptan -- complete relief at 2 hrs

Evidence Table 9. Efficacy of oral sumatriptan -- HA relief at 2 hrs

Evidence Table 10. Efficacy of oral sumatriptan -- complete relief at 2 hrs

Evidence Table 11. Efficacy of oral sumatriptan -- HA relief and complete relief at 4 hrs

Evidence Table 12. Efficacy of intranasal sumatriptan -- HA relief at 1 hr

Evidence Table 13. Efficacy of intranasal sumatriptan -- HA relief at 2 hrs

Evidence Table 14. Efficacy of new 5HT1D-receptor agonists

Evidence Table 15. Efficacy of opiate analgesics

Evidence Table 16. Efficacy of isometheptene and, Midrin®/Midrid®

Evidence Table 17. Adverse events associated with the use of self-administered drug treatments for the acute treatment of migraine

Evidence Table 18. Percentage of patients reporting adverse events (not necessarily drug related) after treatment with subcutaneous sumatriptan (6 mg)

Evidence Table 19. Percentage of patients reporting drug-related adverse events after treatment with subcutaneous sumatriptan (6 mg)

Evidence Table 20. Percentage of patients reporting adverse events (not necessarily drug related) after treatment with oral sumatriptan (25, 50, 100 mg)

Evidence Table 21. Percentage of patients reporting drug-related adverse events after treatment with oral sumatriptan (100 mg)